Clinical trials
Phase 1 Myasthenia Gravis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 15 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 13 |
| Not yet recruiting | 10 |
| Completed | 3 |
| Terminated | 3 |
| Unknown status | 3 |
| Withdrawn | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tongji Hospital | 3 |
| Zhejiang University | 3 |
| Daishi Tian | 2 |
| Tianjin Huanhu Hospital | 2 |
| Ting Chang, MD | 2 |
| Arcellx, Inc. | 1 |
| Baltimore VA Medical Center | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Cabaletta Bio | 1 |
| Candid Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myasthenia Gravis | 37 |
| Multiple Sclerosis | 13 |
| Neuromyelitis Optica | 9 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 7 |
| Autoimmune Diseases of the Nervous System | 5 |
| Lupus Erythematosus, Systemic | 4 |
| Myositis | 4 |
| Scleroderma, Systemic | 4 |
| Autoimmune Diseases | 3 |
| Muscle Weakness | 2 |
Trials
Showing 51 to 37 of 37. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.